SOLUBLE AND MEMBRANE-ANCHORED FORMS OF LASSA VIRUS SUBUNIT PROTEINS

The invention discloses compositions comprising soluble and membrane-anchored forms of Lassa virus (LASV) glycoprotein 1 (GP1), glycoprotein 2 (GP2), the glycoprotein precursor (GPC), the nucleocapsid protein (NP), and the nucleic acids encoding these proteins. This invention further relates to diag...

Full description

Saved in:
Bibliographic Details
Main Authors WILSON, RUSSELL, B, GESKE, F., JON, CASHMAN, KATHLEEN, A, GUTTIERI, MARY, C, BAUSCH, DANIEL, G, KULAKOSKY, PETER, C, MATSCHINER, ALEXANDER, GARRY, ROBERT, F, FAIR, JOSEPH, N, ILLICK, MEGAN, M, SAMPEY, DARRYL, B, BRANCO, LUIS, M
Format Patent
LanguageEnglish
French
Published 19.03.2009
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The invention discloses compositions comprising soluble and membrane-anchored forms of Lassa virus (LASV) glycoprotein 1 (GP1), glycoprotein 2 (GP2), the glycoprotein precursor (GPC), the nucleocapsid protein (NP), and the nucleic acids encoding these proteins. This invention further relates to diagnostic and preventative methods using these compositions. Preventative methods include preparation of vaccines, as well as factors (e.g. small molecules) that inhibit LASV infectivity. Further, the invention relates to diagnostic and therapeutic antibodies including neutralizing antibodies for the prevention and treatment of infection by LASV and other arenaviruses. L'invention concerne des compositions comprenant des formes solubles et ancrées sur membrane de glycoprotéine 1 (GP1), de glycoprotéine 2 (GP2), du précurseur de la glycoprotéine (GPC), de la protéine de nucléocapside (NP) du virus Lassa (LASV) et des acides nucléiques codant pour ces protéines. La présente invention concerne également des procédés de diagnostic et de prévention utilisant ces compositions. Les procédés de prévention comprennent la préparation de vaccins, ainsi que de facteurs (par exemple, petites molécules) qui inhibent le pouvoir infectieux de LASV. En outre, l'invention concerne des anticorps de diagnostic et des anticorps thérapeutiques comprenant des anticorps neutralisants pour la prévention et le traitement d'une infection par LASV et autres arenavirus.
Bibliography:Application Number: WO2008US04622